Neurocrine Biosciences Says Kevin Gorman Will Retire As CEO On October 11, 2024; Kyle Gano Named As Successor
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences announced that CEO Kevin Gorman will retire on October 11, 2024, and will be succeeded by Kyle Gano, Ph.D., the current Chief Business Development and Strategy Officer. Gano will also join the Board of Directors, while Gorman will continue to serve on the Board.
May 28, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Neurocrine Biosciences announced a leadership change with CEO Kevin Gorman retiring on October 11, 2024. Kyle Gano, Ph.D., will take over as CEO and join the Board of Directors. Gorman will remain on the Board.
The announcement of a CEO transition can create uncertainty in the short term, but the continuity provided by Gorman remaining on the Board and Gano's internal promotion may mitigate potential negative impacts.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100